The clinical efficacy and safety of paclitaxel combined with avastin for NSCLC patients diagnosed with malignant pleural effusion
Rev. Assoc. Med. Bras. (1992, Impr.)
; 64(3): 230-233, Mar. 2018. tab, graf
Article
in En
| LILACS
| ID: biblio-896447
Responsible library:
BR1.1
ABSTRACT
Summary Objective:
The current study aimed to investigate the clinical efficacy of paclitaxel combined with avastin for non-small cell lung cancer (NSCLC) patients diagnosed with malignant pleural effusion (MPE).Method:
Total of 33 patients diagnosed with NSCLC as well as malignant pleural effusion were included. All of them received paclitaxel (175 mg/m2) and avastin (5 mg/kg). Clinical efficacy was evaluated using the total response rate, overall survival, progression-free survival and changes in MPE volume. Adverse events and rates of toxicities were examined as well.Results:
The total response rate reached 77% while the overall survival and the median progression-free survival were respectively 22.2 months and 8.4 months. Toxicities of grade 3-4 consisted of neutropenia in 57% of patients, anemia in 17% of them, febrile neutropenia in 11%, as well as anorexia in 7%. No treatment-correlated deaths were found.Conclusion:
Paclitaxel combined with avastin decreased MPE volume and increased survival rate of NSCLC patients via inhibiting vascular endothelial growth factor expression.Key words
Full text:
1
Index:
LILACS
Main subject:
Antineoplastic Combined Chemotherapy Protocols
/
Paclitaxel
/
Carcinoma, Non-Small-Cell Lung
/
Angiogenesis Inhibitors
/
Bevacizumab
/
Lung Neoplasms
/
Antineoplastic Agents, Phytogenic
Type of study:
Diagnostic_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
Language:
En
Journal:
Rev. Assoc. Med. Bras. (1992, Impr.)
Journal subject:
EducaÆo em Sa£de
/
GestÆo do Conhecimento para a Pesquisa em Sa£de
/
MEDICINA
Year:
2018
Type:
Article